5 reasons to invest in AcuCort
1. Innovative product
Zeqmelit® addresses a significant patient need in acute and severe allergic reactions. The medication is a rapidly dissolving oral film that is convenient to carry and easy to place on the tongue, without the need for water.
2. Large market
Approximately 30% of the world’s population suffers from allergic symptoms. The potential market for Zeqmelit® is estimated to be worth more than 3 billion US dollars.
3. Near-term sales launch
The first order has been received, and the plan is for Zeqmelit® to be available in pharmacies in the Nordic countries from the summer of 2024. Intensive efforts are underway to support commercialization and further sales.
4. Low development risk
Zeqmelit® is approved in Sweden, Denmark, Norway, and Finland, where regulatory approvals and agreements with reputable distributors are in place. Registration processes are ongoing in other EU countries and the USA.
5. Competent and experienced team
The management and board have broad and deep experience in commercializing new drugs.